Oppenheimer analyst Leland Gershell maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) today and set a price target ...
H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on CRNX stock, giving a Buy rating on January 10.Stay Ahead of the ...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...